Ela Pharma

Necrosis Inhibition Technology

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2015
Last updated 2026-06-18
Total raised
$77K
Last: 2020-12
Stage
Seed
Founded
2015
Headcount
2
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis. The companys drug-development process is based on a new platform for anti-necrosis technology. The prevention and treatment of necrosis is significant to the treatment of numerous pathological conditions and diseases. Ela Pharmas technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathways. Ela Pharmas first line of anti-necrosis agents is based on small molecules with structural features suitable for inhibiting a specific cellular target, which were found to significantly inhibit cell necrosis at particularly low concentrations.

Funding history · 2 rounds · $77K total

2020-12
Undisclosed
2019-12
Grant $77K

Q&A

What is Ela Pharma's primary focus?
Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis, utilizing a new platform for anti-necrosis technology.
Where is Ela Pharma headquartered?
Ela Pharma is headquartered in Tel Aviv-Yafo, Israel.
When was Ela Pharma founded?
Ela Pharma was founded in June 2015.
How many employees does Ela Pharma have?
Ela Pharma has 1-10 employees.
Who are the co-founders of Ela Pharma?
The co-founders of Ela Pharma are Roi Paul Nathan, who also serves as CEO, and Ilana Nathan.
What is Ela Pharma's current funding stage?
Ela Pharma is currently in the Seed funding stage.
Has Ela Pharma received any grant funding?
Yes, Ela Pharma received a Grant round in December 2019 from EU Horizon 2020, totaling $77,000.
What is Ela Pharma's technology based on?
Ela Pharma's technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme critical in regulating necrosis pathways, using small molecules as anti-necrosis agents.
Does Ela Pharma hold any patents?
Yes, Ela Pharma holds 1 patent.

Team · 2

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalsdrug-developmentcell-therapyamyotrophic-lateral-sclerosis-alsstrokeheart-diseasesbiotechnologyischemiadegenerative-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteelapharma.com/
LinkedInlinkedin.com/company/18221536

Identifiers & details

Founded2015-6
Employees (exact)2

Radar intelligence

Patents

EPO1

Web history (Wayback)

Domainelapharma.com

Certificate / subdomain footprint

Subdomains2